Download PDF
Viszeralchirurgie 2007; 42(4): 249-258
DOI: 10.1055/s-2007-981251
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Interventionelle Verfahren zur Therapie von Lebertumoren

Interventional Treatment of Liver TumorsA. Lubienski1 , T. Eckey1 , K. Lubienski1 , R.-T. Hoffmann2 , T. F. Jakobs2 , T. Helmberger3 , J. Gellissen1
  • 1Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
  • 2Abteilung Klinische Radiologie, Universität München, Campus Großhadern
  • 3Institut für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Städtisches Klinikum München GmbH, Klinikum Bogenhausen
Further Information

Publication History

Publication Date:
23 August 2007 (online)

    Permissions and Reprints

Zusammenfassung

Metastasen gastrointestinaler Tumoren repräsentieren in der westlichen Welt die häufigste Ursache für sekundäre, das Leberzellkarzinom (HCC) für primäre Lebertumoren. Aus der Gesamtheit dieser Patienten mit primären oder sekundären Lebermalignomen sind lediglich 20-30% einer operativen Therapie mit kurativem Ansatz zuführbar. In nicht-resektablen Situationen sind interventionelle Therapieverfahren wie die transarterielle Chemoembolisation (TACE), die perkutane Alkoholinstillationstherapie (PAIT), die perkutane Radiofrequenzablation (RFA) und die selektive interne Radiotherapie (SIRT) alternative Therapieoptionen, welche im Therapiekonzept aufgrund niedriger Nebenwirkungs- und guter Tumorkontrollraten zunehmend an Bedeutung gewinnen. Aktuelle Studienergebnisse an großen Patientenkollektiven demonstrieren den guten und langfristigen Erfolg der TACE bei nicht-operablen HCCs. Eine mehrzeitige interventionelle Kombinationstherapie ist möglich und sinnvoll. Eine Kombinationstherapie von TACE und PAIT verbessert nachweislich selbst bei großen HCCs (bis 7 cm) die Überlebensrate. Gemäß international anerkannter Empfehlungen der EASL (European Association for the Study of the Liver) wird die PAIT nach der Resektion als Verfahren zweiter Wahl bei der Therapie bis zu drei HCCs kleiner 3 cm gesehen. Die RFA findet sowohl bei primären als auch sekundären hepatischen Malignomen Einsatz. Neuere Studien belegen die Überlegenheit der RFA gegenüber der PAIT hinsichtlich Invasivität, lokaler Ansprechrate und Überleben. Die SIRT findet Einsatz bei multifokalem, ansonsten nicht mehr behandelbarem Leberbefall. Die SIRT verhindert in den meisten Fällen den Tumorprogress insbesondere auch nach vorangegangener erfolgloser Chemotherapie mit modernen Kombinationen (Oxalaplatin, Irinotecan). Aufgrund eines niedrigen Evidenzlevels der meisten Studien ist eine abschließende Bewertung lokal-ablativer Verfahren verfrüht, eine deutliche Lebenszeitverlängerung bei Patienten mit ursprünglich schlechter Prognose zeichnet sich jedoch ab.

Schlüsselwörter

minimalinvasive Therapie - Lebermetastasen - hepatozelluläres Karzinom - Radiofrequenzablation - Alkoholablation - transarterielle Chemoembolisation - selektive interne Radiotherapie

Literatur

  • 1 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340 745-750
    CrossrefPubMedGoogle Scholar
  • 2 Lencioni R, Crocetti L, Cioni D, della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases.  Invest Radiol. 2004;  39 689-697
    CrossrefPubMedGoogle Scholar
  • 3 Choti M A, Bulkley G B. Management of hepatic metastases.  Liver Transplantation Surg. 1999;  5 65-80
    PubMedGoogle Scholar
  • 4 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
    CrossrefPubMedGoogle Scholar
  • 5 Jonker D J, Maroun J A, Kocha W. Survival benefit of chemotherapy in metastatic colrectal cancer: a meta-analysis of randomized controlled trials.  Br J Cancer. 2000;  82 1789-1794
    CrossrefPubMedGoogle Scholar
  • 6 Huppert P E, Lauchart W, Duda S H, Torkler C, Kloska S P, Weinlich M, Benda N, Pereira P, Claussen C D. Chemoembolization of hepatocellular carcinomas: Which factors determine therapeutic response and survival?.  Fortschr Röntgenstr. 2004;  176 375-385
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.  Cancer. 2000;  88 50-57
    CrossrefPubMedGoogle Scholar
  • 8 Lewis A L, Gonzalez M V, Lloyd A W, Hall B, Tang Y, Willis S L, Leppard S W, Wolfenden L C, Palmer R R, Stratford P W. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.  J Vasc Interv Radiol. 2006;  17 335-342
    CrossrefPubMedGoogle Scholar
  • 9 Varela M, Real M I, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet J M, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.  J Hepatol. 2007;  46 474-481
    CrossrefPubMedGoogle Scholar
  • 10 Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma.  Cancer. 2000;  88 1574-1581
    CrossrefPubMedGoogle Scholar
  • 11 Matsui O, Kadoya M, Yoshikawa J, Gaabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization.  Radiology. 1993;  188 79-83
    PubMedGoogle Scholar
  • 12 Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.  Hepatology. 2003;  37 429-442
    CrossrefPubMedGoogle Scholar
  • 13 Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Liver Cancer Study Group of Japan . Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients.  Gastroenterology. 2006;  131 461-469
    CrossrefPubMedGoogle Scholar
  • 14 Ho A S, Picus J, Darcy M D, Tan B, Gould J E, Pilgram T K, Brown D B. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.  Am J Roentgenol. 2007;  188 1201-1207
    CrossrefPubMedGoogle Scholar
  • 15 Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, Kawasaki H. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study.  Cancer. 2001;  92 1516-1524
    CrossrefPubMedGoogle Scholar
  • 16 Lubienski A, Bitsch R G, Schemmer P, Grenacher L, Düx M, Kauffmann G W. Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy.  Fortschr Röntgenstr. 2004;  176 1794-1802
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Livraghi T, Goldberg S N, Lazzaroni S, Meloni F, Solbiati L, Gazelle G S. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.  Radiology. 1999;  210 655-661
    CrossrefPubMedGoogle Scholar
  • 18 Lencioni R A, Allgaier H P, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum H E, Bartolozzi C. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermalablation versus percutaneous ethanol injection.  Radiology. 2003;  228 235-240
    CrossrefPubMedGoogle Scholar
  • 19 Livraghi T, Giorgio A, Marin G, Salmi A, Sio I, Bolondi L, Pompili M, Brunello F, Lazzaroni S, Torzilli G, Zucchi A. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.  Radiology. 1995;  197 101-108
    CrossrefPubMedGoogle Scholar
  • 20 Lin S M, Lin C J, Lin C C, Hsu C W, Chen Y C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.  GUT. 2005;  54 1151-1156
    CrossrefPubMedGoogle Scholar
  • 21 Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma.  Cancer. 1998;  83 48-57
    CrossrefPubMedGoogle Scholar
  • 22 Lencioni R, Pinto F, Armillotta N, Bassi A M, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, Bartolozzi C. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience.  Eur Radiol. 1997;  7 514-519
    CrossrefPubMedGoogle Scholar
  • 23 Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma.  Clin Liver Dis. 2005;  9 301-314
    CrossrefPubMedGoogle Scholar
  • 24 Bleicher R J, Allegra D P, Nora D T, Wood T F, Foshag L J, Bilchik A J. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned.  Ann Surg Oncol. 2003;  10 52-58
    CrossrefPubMedGoogle Scholar
  • 25 Bruix J, Sala M, Llovet J M. Chemoembolization for hepatocellular carcinoma.  Gastroenterology. 2004;  127 (Suppl 1) 179-188
    CrossrefPubMedGoogle Scholar
  • 26 Choi B I, Kim H C, Han J K, Park J H, Kim Y I, Kim S T, Lee H S, Kim C Y, Han M C. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings.  Radiology. 1992;  182 709-713
    PubMedGoogle Scholar
  • 27 Gillams A R, Lees W R. Radio-frequency ablation of colorectal liver metastases in 167 patients.  Eur Radiol. 2004;  14 2261-2267
    CrossrefPubMedGoogle Scholar
  • 28 Bruix J, Sherman M, Llovet J M, Beaugrand M, Lencioni R, Burroughs A K, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J Hepatol. 2001;  35 421-430
    CrossrefPubMedGoogle Scholar
  • 29 Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, Hata Y, Niwa Y, Shiratori Y, Terano A. et al . Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study.  Cancer. 1991;  68 1524-1530
    PubMedGoogle Scholar
  • 30 Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection.  Jpn J Clin Oncol. 1998;  28 604-608
    CrossrefPubMedGoogle Scholar
  • 31 Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.  Hepatology. 2000;  32 1224-1229
    CrossrefPubMedGoogle Scholar
  • 32 Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center.  Liver Transpl. 2004;  10 (Suppl 1) 98-106
    CrossrefPubMedGoogle Scholar
  • 33 Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation.  Gastroenterology. 2004;  127 (Suppl 1) 159-166
    CrossrefPubMedGoogle Scholar
  • 34 Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F, Saisho H. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation.  J Hepatol. 2005;  43 458-464
    CrossrefPubMedGoogle Scholar
  • 35 Di Stasi M, Buscarini L, Livraghi T, Giorgio A, Salmi A, De Sio I, Brunello F, Solmi L, Caturelli E, Magnolfi F, Caremani M, Filice C. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates.  Scand J Gastroenterol. 1997;  32 1168-1173
    CrossrefPubMedGoogle Scholar
  • 36 Khan K N, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.  J Hepatol. 2000;  32 269-278
    CrossrefPubMedGoogle Scholar
  • 37 Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T, Kawasaki H, Ikawa S. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma.  Cancer. 2000;  88 529-537
    CrossrefPubMedGoogle Scholar
  • 38 Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy.  Radiology. 2002;  223 331-337
    CrossrefPubMedGoogle Scholar
  • 39 Lin S M, Lin C J, Lin C C, Hsu C W, Chen Y C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm.  Gastroenterology. 2004;  127 1714-1723
    CrossrefPubMedGoogle Scholar
  • 40 Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, Tateishi R, Imamura M, Hamamura K, Teratani T, Shiina S, Ishikawa T, Omata M. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.  Liver International. 2004;  24 625-630
    CrossrefPubMedGoogle Scholar
  • 41 Huang G T, Lee P H, Tsang Y M, Lai M Y, Yang P M, Hu R H, Chen P J, Kao J H, Sheu J C. Percutaneous ethanol injection versus surgical resection for the treatment ofsmall hepatocellular carcinoma: a prospective study.  Ann Surg. 2005;  242 36-42
    CrossrefPubMedGoogle Scholar
  • 42 Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.  Gastroenterology. 2005;  129 122-130
    CrossrefPubMedGoogle Scholar
  • 43 Shibata T, Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode.  Radiology. 2006;  238 346-353
    PubMedGoogle Scholar
  • 44 Goldberg S N, Gazelle G S, Compton C C, Mueller P R, Tanabe K K. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.  Cancer. 2000;  88 2452-2463
    CrossrefPubMedGoogle Scholar
  • 45 Livraghi T, Goldberg S N, Lazzaroni S, Meloni F, Ierace T, Solbiati L, Gazelle G S. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.  Radiology. 2000;  214 761-768
    CrossrefPubMedGoogle Scholar
  • 46 Goldberg S N, Grassi C J, Cardella J F, Charboneau J W, Dodd III G D, Dupuy D E, Gervais D, Gillams A R, Kane R A, Lee Jr  F T, Livraghi T, McGahan J, Phillips D A, Rhim H, Silverman S G. Image-guided tumor ablation: standardization of terminology and reporting criteria.  Radiology. 2005;  235 728-739
    CrossrefPubMedGoogle Scholar
  • 47 Pereira P, Boss A, Clasen S, Gouttefangeas C, Schmidt D, Claussen C D. Radiofrequency ablation: the percutaneous approach.  Recent Result Cancer Res. 2006;  167 39-52
    PubMedGoogle Scholar
  • 48 Stroszczynski C, Gaffke G. Use of imaging modalities for the guidance of minimally invasive tumor therapies (MITT).  Recent Result Cancer Res. 2006;  167 3-12
    PubMedGoogle Scholar
  • 49 Lubienski A, Leibecke T, Helmberger T. Liver metastases.  Recent Results Cancer Res. 2006;  167 79-89
    PubMedGoogle Scholar
  • 50 Solbiati L, Goldberg S N, Ierace T, Livraghi T, Meloni F, Dellanoce M, Sironi S, Gazelle G S. Hepatic metastases: percutaneous radio-frequency ablation with cooled tipp electrodes.  Radiology. 1997;  205 367-373
    PubMedGoogle Scholar
  • 51 Lencioni R, Goletti O, Armillotta N, Paolicchi A, Moretti M, Cioni D, Donati F, Cicorelli A, Ricci S, Carrai M, Conte P F, Cavina E, Bartolozzi C. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial.  Eur Radiol. 1998;  8 1205-1211
    CrossrefPubMedGoogle Scholar
  • 52 Gillams A R, Lees W R. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer.  Dis Colon Rectum. 2000;  43 656-661
    CrossrefPubMedGoogle Scholar
  • 53 Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases.  Eur J Ultrasound. 2001;  13 149-158
    CrossrefPubMedGoogle Scholar
  • 54 Oshowo A, Gillams A, Harrison E, Lees W R, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases.  Br J Surg. 2003;  90 1240-1243
    CrossrefPubMedGoogle Scholar
  • 55 Abdalla E K, Vauthey J N, Ellis L M, Ellis V, Pollock R, Broglio K R, Hess K, Curley S A. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.  Ann Surg. 2004;  239 818-825 , discussion 825-827
    CrossrefPubMedGoogle Scholar
  • 56 Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1 000 cases.  Cancer. 2005;  103 1201-1209
    CrossrefPubMedGoogle Scholar
  • 57 Chen M H, Wei Y, Yan K, Gao W, Dai Y, Huo L, Yin S S, Zhang H, Poon R T. Treatment strategy to optimize radiofrequency ablation for liver malignancies.  J Vasc Interv Radiol. 2006;  17 671-683
    CrossrefPubMedGoogle Scholar
  • 58 Choi D, Lim H K, Rhim H, Kim Y S, Lee W J, Paik S W, Koh K C, Lee J H, Choi M S, Yoo B C. Percutaneous radiofrequency ablation for early stage hepatocellular carcinoma as a first line treatment: long-term results and prognostic factors in a large single-institution series.  Eur Radiol. 2007;  17 684-692
    CrossrefPubMedGoogle Scholar
  • 59 Choi D, Lim H K, Rhim H, Kim Y S, Yoo B C, Paik S W, Joh J W, Park C K. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors.  Ann Surg Oncol. 2007;  , ; Epub ahead of print
    PubMedGoogle Scholar
  • 60 Sorensen S M, Mortensen F V, Nielsen D T. Radiofrequency ablation of colorectal liver metastases: long-term survival.  Acta Radiol. 2007;  48 253-258
    CrossrefPubMedGoogle Scholar
  • 61 Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, De Wever I, Michel L. Complications of radiofrequency coagulation of liver tumours.  Br J Surg. 2002;  89 1206-1222
    CrossrefPubMedGoogle Scholar
  • 62 De Baere T, Risse O, Kuoch V, Dromain C, Sengel C, Smayra T, El Din M G, Letoublon C, Elias D. Adverse events during radiofrequency treatment of 582 hepatic tumors.  AJR. 2003;  181 695-700
    PubMedGoogle Scholar
  • 63 Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma.  Br J Surg. 2005;  92 856-858
    CrossrefPubMedGoogle Scholar
  • 64 Llovet J M, Vilana R, Bru C, Bianchi L, Salmeron J M, Boix L, Ganau S, Sala M, Pages M, Ayuso C, Sole M, Rodes J, Bruix J. Barcelona Clinic Liver Cancer (BCLC) Group . Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.  Hepatology. 2001;  33 1124-1129
    CrossrefPubMedGoogle Scholar
  • 65 Jaskolka J D, Asch M R, Kachura J R, Ho C S, Ossip M, Wong F, Sherman M, Grant D R, Greig P D, Gallinger S. Needle tract seeding after radiofrequency ablation of hepatic tumors.  J Vasc Interv Radiol. 2005;  16 485-491
    CrossrefPubMedGoogle Scholar
  • 66 Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.  Ann Oncol. 2001;  12 1711-1720
    CrossrefPubMedGoogle Scholar
  • 67 Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardazi G, Gray B. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus flourouracil/leucovorin chemotherapy alone in advanced colorectal cancer.  J Surg Oncol. 2004;  88 78-85
    CrossrefPubMedGoogle Scholar
  • 68 Jakobs T F, Hoffmann R T, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubienski A, Reiser M F, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using90Yttrium resin-microspheres.  Eur Radiol. 2007;  17 1320-1330
    CrossrefPubMedGoogle Scholar

Dr. med. A. Lubienski

Klinik für Radiologie und Nuklearmedizin · Universitätsklinikum Schleswig-Holstein · Campus Lübeck

Ratzeburger Allee 160

23538 Lübeck

Phone: +49/4 51/5 00 21 29

Fax: +49/4 51/5 00 64 97

Email: andreas.lubienski@uk-sh.de

      >